Today announced the closing of a $21.

Alvine Pharmaceuticals raises funds for Phase 2a medical trial of its lead compound ALV003 Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical business centered on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced the closing of a $21.5 million extension of its Series A financing sildenafil 100mg how to take . New investor Panorama Capital led the funding round, joining founding traders InterWest Partners, Prospect Venture Partners, Sofinnova Ventures, Dark River Asset Flagship and Management Ventures. Arises from the Series A expansion will fund the Company’s recently initiated Phase 2a scientific trial of its lead compound ALV003 for the treatment of celiac disease.D., President and CEO of Alvine.D.